

~ Updates on HPMS Memos ~

<b>CMS Memo Title &amp; Release Date</b>	2021 Part C and D Reporting Requirements Data Validation Results – Dated 09/23/2021
<b>Summary</b>	CMS released the results of the data validation reviews conducted between April 1, 2021, and June 30, 2021, for CY 2021 Medicare Part C and D data.
<b>Action</b>	Informational to PACE as PACE is excluded from the Part C reporting requirements and waived of the Part D reporting requirements.
<b>CMS Memo Title &amp; Release Date</b>	Encounter Data Front End System Updates - Combined Common Edits and Enhancements Module Updates – Dated 09/27/2021
<b>Summary</b>	The Centers for Medicare and Medicaid Services (CMS) continues to implement software improvements to the systems related to accepting and processing encounter data to support the Medicare Advantage (MA) program. The most recent update is effective <b>October 4<sup>th</sup>, 2021</b> and will be related to the Early & Periodic Screening, Diagnosis, and Treatment (EPSDT) Condition Indicator. Refer to the memo for more details.
<b>Action</b>	Applicable to PACE.
<b>CMS Email Title &amp; Release Date</b>	Coverage Gap Discount Program: October Participating Labeler Codes – Dated 09/29/2021
<b>Summary</b>	CMS will make the following updates to the list of participating manufacturer labeler codes by <b>October 1<sup>st</sup>, 2021</b> .  Added: 73380 AstraZeneca Pharmaceuticals LP
<b>Action</b>	Although the Coverage Gap Discount Program does not apply to PACE, the participating labeler codes are applicable because only brand name prescriptions with NDCs from these codes are accepted for Part D payment. Pharmastar has made the necessary software adjustments to accommodate for the updated codes.
<b>CMS Memo Title &amp; Release Date</b>	State Health Insurance Assistance Program (SHIP) UniqueID Program – Dated 09/29/2021

<b>Summary</b>	CMS releases an updated memorandum regarding contract year (CY) 2021 Drug Management Programs (DMPs). Updates and changes are in red italicized font.
<b>Action</b>	Applicable to PACE.

<b>CMS Memo Title &amp; Release Date</b>	Updates to the Drug Data Processing System – Dated 09/30/2021
<b>Summary</b>	<p>CMS explains upcoming changes to the Drug Data Processing System (DDPS).</p> <ul style="list-style-type: none"> <li>• Update to Tier – Field 51</li> <li>• Update to Edit Code 870</li> <li>• New PDE field – Part D Model Indicator</li> <li>• Changes to Edit Code 706 and 707</li> </ul> <p>For the updated PDE Edit Code Listing spreadsheet, PDE Inbound File Layout, and PDE Outbound File Layout refer to the Customer Service and Support Center (CSSC) Operations website at <a href="http://www.csscooperations.com">http://www.csscooperations.com</a>.</p>
<b>Action</b>	Refer to memo for complete details.

<b>CMS Memo Title &amp; Release Date</b>	2022 Medicare Star Ratings Marketing Template – Dated 09/30/2021
<b>Summary</b>	This is a reminder to alert plans that the 2022 Medicare Star Ratings marketing template will be available in HPMS along with the release of the 202 Star Ratings on the Medicare Plan Finder. Plans may not release information on their 2022 Star Ratings through any means until the ratings have been released publicly and are live on the MPF. Links for additional guidance is included in the email.
<b>Action</b>	Refer to memo for complete details.

<b>CMS Memo Title &amp; Release Date</b>	2022 Reassignment of Low-Income Subsidy Beneficiaries in Non-Renewing Medicare Advantage Plans and Medicare Advantage Plans Reducing their Service Areas – Dated 10/01/2021
--	---

<b>Summary</b>	In October, CMS will conduct reassignment of beneficiaries eligible for LIS who are enrolled in certain Medicare Advantage plans. CMS will reassign only individuals who are LIS-eligible in 2021 and 2022; also if they are enrolled in a MA plan that will be non-renewing or has a service area reduction.
<b>Action</b>	Informational to PACE. Refer to the memo for additional information and detail on the process in the event that such reassignment affects your participants

<b>CMS Memo Title &amp; Release Date</b>	2022 Reassignment of Low-Income Subsidy Beneficiaries in Prescription Drug Plans – dated 10/01/2021
<b>Summary</b>	<p>CMS will reassign individuals who are LIS-eligible in 2021, will remain LIS-eligible in 2022, and—</p> <ol style="list-style-type: none"> <li>1. Have remained in the PDP into which CMS originally assigned them, but their current PDP will no longer have a Part D premium at or below the LIS benchmark in 2021 (excluding the PDPs that volunteer to waive the de minimis amount); or,</li> <li>2. Are enrolled in a PDP that will be non-renewing, regardless of whether they chose or were assigned to the PDP.</li> <li>3. Are in MA plans that are non-renewing or reducing their service area as of 2021. LIS-eligible beneficiaries in non-renewing MA plans or beneficiaries affected by a service area reduction are reassigned into PDPs only.</li> </ol> <p>Additional information about the reassignment process for qualifying beneficiaries in MA plans that are non-renewing or reducing their service area will be provided in separate guidance.</p>
<b>Action</b>	Informational to PACE. PACE organizations should review the memo for items that may be applicable in the event such reassignment affects your participants.

<b>CMS Memo Title &amp; Release Date</b>	
<b>Summary</b>	

<b>Action</b>	
<b>CMS Memo Title &amp; Release Date</b>	
<b>Summary</b>	
<b>Action</b>	

<b>CMS Memo Title &amp; Release Date</b>	
<b>Summary</b>	
<b>Action</b>	

<b>CMS Memo Title &amp; Release Date</b>	
<b>Summary</b>	
<b>Action</b>	

**For the latest CMS response to COVID-19, please visit the [CMS.gov](https://www.cms.gov) website.**

Please note that this information is provided to you in summary form for general informational purposes only and does not constitute legal or regulatory compliance advice. It is your responsibility to consult with your Compliance Officer and/or legal counsel to determine applicability of any regulation or standards referenced herein to your organization and/or processes.